Ameritas Investment Partners’s Abeona Therapeutics ABEO Stock Holding History

Ameritas Investment Partners’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20K	Hold	4,459	–	–	﹤0.01%	2597
2025 Q4	$23.5K	Hold	4,459	–	–	﹤0.01%	2559
2025 Q3	$23.5K	Hold	4,459	–	–	﹤0.01%	2585
2025 Q2	$25.3K	Buy	+4,459	New	+$25.4K	﹤0.01%	2553
2021 Q2	–	Sell	-208	Closed	-$10K	–	3044
2021 Q1	$10K	Hold	208	–	–	﹤0.01%	2843
2020 Q4	$8K	Hold	208	–	–	﹤0.01%	2866
2020 Q3	$5K	Buy	208 +100	+93%	+$6.3K	﹤0.01%	2960
2020 Q2	$8K	Hold	108	–	–	﹤0.01%	2801
2020 Q1	$6K	Hold	108	–	–	﹤0.01%	2733
2019 Q4	$9K	Hold	108	–	–	﹤0.01%	2757
2019 Q3	$6K	Hold	108	–	–	﹤0.01%	2880
2019 Q2	$13K	Hold	108	–	–	﹤0.01%	2674
2019 Q1	$20K	Hold	108	–	–	﹤0.01%	2365
2018 Q4	$19K	Hold	108	–	–	﹤0.01%	2355
2018 Q3	$35K	Hold	108	–	–	﹤0.01%	2184
2018 Q2	$43K	Buy	108 +23	+27%	+$10.1K	﹤0.01%	2084
2018 Q1	$30K	Hold	85	–	–	﹤0.01%	2200
2017 Q4	$34K	Hold	85	–	–	﹤0.01%	2138
2017 Q3	$27K	Hold	85	–	–	﹤0.01%	2250
2017 Q2	$14K	Buy	+85	New	+$11.6K	﹤0.01%	2646

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameritas Investment Partners's ABEO Position: Q1 2026 in Review

Ameritas Investment Partners held its Abeona Therapeutics (ABEO) position steady in Q1 2026 at 4,459 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #2597.

Ameritas Investment Partners first reported a position in ABEO in Q2 2017 and has held it in 20 quarters since. The position peaked at $43K in Q2 2018. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

Ameritas Investment Partners held 4,459 shares of Abeona Therapeutics worth $20K as of Q1 2026.
Ameritas Investment Partners left its Abeona Therapeutics share count unchanged in Q1 2026.
Abeona Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2597 holding.
Ameritas Investment Partners first reported a position in Abeona Therapeutics in Q2 2017 and has held it in 20 quarters since.
Ameritas Investment Partners's Abeona Therapeutics position peaked at $43K in Q2 2018.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.